Press Releases

21 Dec 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") has announced today that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart. Subject to Health Canada's approval of Shoppers Drug Mart's application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with MedReleaf branded medical cannabis products. It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies. "From inception, MedReleaf has been focused on setting the standard for patient care in our industry and producing consistent, high quality medicine," said Neil Closner, CEO of MedReleaf. "With this agreement, we look forward to making our award-winning strains available as the trusted provider of premium cannabis-based pharmaceutical products to the largest pharmacy retailer in Canada." About MedReleaf Corp. MedReleaf sets The Medical Grade ...
4 Dec 2017.
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES ./ MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") is pleased to announce that it has completed its previously announced offering (the "Offering"), on a "bought deal" basis, pursuant to a short form prospectus, of an aggregate of 6,072,600 common shares of the Company (the "Offered Shares") at a price of $16.55 per Offered Share (the "Offering Price"). The Company offered and sold a total of 3,625,470 Offered Shares (the "Treasury Offering"), and an aggregate of 2,447,130 Offered Shares were offered and sold by certain selling shareholders of the Company (the "Secondary Offering"), namely: Zola Finance Inc., Rayray Investments Inc., Baronford Capital Corporation, AJA Holdings 2013 Inc. and MENA Investment Network Inc. (collectively, the "Selling Shareholders"), resulting in aggregate gross proceeds of ...
1 Dec 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, is proud to announce that it won a total of 10 prestigious awards – more than any other LP – at the 2017 edition of the Canadian Cannabis Awards including Top Licensed Producer. In addition to Top LP, MedReleaf won a number of other categories including: Top Indica Flower , Sedamen

Top High CBD Flower, Avidekel

Top High THC Flower, Eran Almog

Top High CBD Oil, Avidekel "I am incredibly proud of our showing at the Canadian Cannabis Awards this year. Taking top spot in four categories, in addition to Top LP , is a testament to the hard work of every single member of the MedReleaf team and the support of our loyal patient base," noted Neil Closner , CEO of MedReleaf . MedReleaf rounded out its total of 10 awards with second place finishes in top customer service, packaging, compassionate pricing and top ...
14 Nov 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today announced that its Australian joint venture partner, Indica Industries Pty Ltd. (t/a "MedReleaf Australia"), has been granted a licence from the Australian Government Office of Drug Control ("ODC") for the cultivation and production of medical cannabis. The licence to undertake authorized cannabis activities commences on November 10, 2018 in order to allow time to complete infrastructure development of the facility. "We're focused on international expansion in countries with a federal legal framework for cannabis, and Australia is an attractive market with a population about two thirds the size of Canada and a focus on medicinal applications," said Neil Closner, CEO of MedReleaf.  "Providing our expertise to local partners allows us to participate in a greater number of international markets in a capital efficient way." MedReleaf , ...
14 Nov 2017.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") announced today that it has entered into an agreement with GMP Securities L.P. , on its own behalf and on behalf of a syndicate of underwriters (the "Underwriters"), pursuant to which the Underwriters will purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 6,072,600 common shares (the "Common Shares") of the Company at a price of $16.55 per Common Share (the "Offering Price") from the Company and Zola Finance Inc. , Rayray Investments Inc. , Baronford Capital Corporation , AJA Holdings 2013 Inc. and MENA Investment Network Inc. as selling shareholders (collectively, the "Selling Shareholders") for aggregate gross proceeds of $100.5 million , with MedReleaf and the Selling Shareholders receiving gross proceeds ...
13 Nov 2017.
MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the second quarter fiscal 2018 ending September 30, 2017 . All amounts expressed are in Canadian dollars unless otherwise noted. "In the second quarter, we increased average selling price and lowered cash costs per gram sold, and this drove improvement from the first quarter to adjusted product contribution margin per gram," said Neil Closner, CEO of MedReleaf. "This margin provides us with greater flexibility in our business model to adapt to changes and operate profitably as the industry evolves, and we are ideally positioned for growth now that the full impact of the Veterans Affairs Policy ("VAC") changes on capping price and volume are behind us." Second Quarter Fiscal 2018 Financial Summary Three months
September 30, CAD$ (in 000s, except grams sold) 2017 2016
Dried Cannabis 7,693 ...
9 Nov 2017.
Canadian patients are increasingly turning to medical cannabis for relief.  As of June 2016 , there were approximately 75,000 Canadians registered to purchase medical cannabis from a licensed producer and that grew to over 200,000 a year later. i While patient demand is evident, the physician community is looking for more scientific evidence before they embrace the widespread recommendation of cannabis for use as a medicine. ii There is a need to address the primary areas of concern for physicians and to bring increased certainty and clarity when prescribing.  For that reason, MedReleaf Corp. (TSX: LEAF), a leading Canadian medical cannabis producer, is introducing a ground-breaking, patent-pending, new genetic test called ReleafDxTM. This novel test analyzes a patient's DNA and health conditions to provide physicians with answers to two key questions: 1) what dosage should be prescribed; and 2) what cannabis product will work best for each individual. "Physicians are getting requests ...
6 Nov 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, has been granted an amended licence from Health Canada to permit sales of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") at its second facility in Bradford, ON ("Bradford Facility"). This increases the Company's total current licensed production and sales capacity by 80% to approximately 12,600 kg per year. "Just 6 months after receiving our cultivation licence at Bradford, we are among the fastest producers to receive a sales licence and have completed multiple harvests at best-in-class cultivation yields of 300 grams per square foot," said Neil Closner, CEO of MedReleaf. "As our industry grows, our proven ability to execute large scale projects while maintaining the highest quality standards further solidifies MedReleaf as a trusted leader amongst licensed producers." This latest amended license from ...
27 Oct 2017.
MedReleaf Corp. (TSX: LEAF), North America's first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products, today announced that it will hold a conference call to discuss its second quarter fiscal 2018 results on Monday, November 13, 2017 at 8:00 a.m. (ET) . The call will be hosted by Neil Closner , Chief Executive Officer, and Igor Gimelshtein , Chief Financial Officer, followed by a question and answer period. MedReleaf will report its financial results in the morning prior to the call. Second Quarter Fiscal 2018 Conference Call Details: Date: Monday, November 13, 2017 Time: 8:00 a.m. (ET) Dial in number: (647) 427-7450 or 1-888-231-8191 Live webcast: http://bit.ly/2yKrLWE Webcast will be archived for 90 days Replay: 1-855-859-2056 Available until November 20, 2017 Replay passcode: 9796804 About MedReleaf Corp. MedReleaf sets The Medical Grade Standard ™ for cannabis in Canada and around the world.  The first and only ICH-GMP and ISO 9001 certified ...
17 Oct 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, welcomes and supports the clarity provided by the Staff Notice issued by the Toronto Stock Exchange ("TSX") on October 16, 2017 which the Company believes levels the playing field for listed cannabis issuers in Canada . Since its listing, MedReleaf has been and continues to operate with the goal of being at all times fully compliant with the TSX requirements pursuant to Sections 306, Section 325, and Part VII (collectively the "Requirements") in the TSX Company Manual and is confident that the review and enforcement of the Staff Notice will have no impact on its operations or listing on the TSX. "The TSX Staff Notice removes the uncertainty for issuers that were already adhering to the Requirements and validates our strategy of focusing on markets that are federally legal and offer federal regulatory guidelines," said Neil Closner , CEO of ...
4 Oct 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today announced the launch of a topical cream, the first Canadian Licensed Producer to do so. The cream is specifically formulated to provide superior absorption with MedReleaf's award-winning high CBD strain and was developed in response to patient feedback for topical applications of CBD. MedReleaf Topical Cream mixes and integrates with the cannabis oil to create an easy-to-use topical agent for direct application to affected areas. "Our product development team has devised a method to provide Canadian patients with a much sought-after, high-absorption, topical cream that is within the strict limitations afforded by the current regulations," said Neil Closner , CEO of MedReleaf . "This is further evidence of MedReleaf's continued leadership in setting the standard for product innovation and focus on the patient experience." "The Dermatology ...
25 Sep 2017.
MedReleaf Corp. (TSX: LEAF) (" MedReleaf " or the " Company ") announced the results of the vote on the election of directors at the annual meeting of shareholders held today. On a vote by ballot, each of the five nominees proposed by management was elected as a director of the Company to hold office until the close of the next annual meeting of shareholders or until the director's successor is elected or appointed. Nominee Votes For % For Votes Withheld % Withheld Norma Beauchamp 55,205,572 99.92% 43,127 0.08%




Neil Closner 55,204,807 99.92% 43,892 0.08% Ronald Funk 55,204,047 99.92% 44,652 0.08%




Deborah Rosati 55,203,372 99.92% 45,327 0.08% Lloyd M. Segal 55,205,147 99.92% 43,552 0.08% About MedReleaf Corp. MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICHGMP and ISO 9001 certified cannabis producer in North America , MedReleaf is a R&D-driven company ...
20 Sep 2017.
MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has been added to the North American Marijuana Index (the "Index") as part of its quarterly rebalancing, and by extension, included in the Horizon Medical Marijuana Life Sciences ETF (TSX: HMMJ) ("HMMJ"). "MedReleaf's addition to the North American Marijuana Index is a recognition of our position as one of the industry's largest and most respected cannabis producers. We have achieved this position through our relentless focus on serving our patients and we will continue to focus on driving growth and profitability in our business to create long-term shareholder value," said Neil Closner, CEO of MedReleaf. "Our inclusion in Horizon's Medical Marijuana Life Sciences ETF provides another avenue for investors to participate in our growth." The HMMJ is the world's first exchange-traded fund to offer direct exposure to the performance ...
14 Sep 2017.
Flora Fotonica Ltd. ("Flora Fotonica"), a developer of advanced grow light technologies for the Cannabis industry and MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, are pleased to announce the signing of a binding agreement to invest and collaborate on the research and development of specialized grow lighting systems for cannabis cultivation. Flora Fotonica will provide MedReleaf with exclusive access to its proprietary LED lighting technology and MedReleaf will dedicate licensed growing space, laboratories, and research personnel. Financial terms of the agreement are not disclosed. "We have a deep connection to the world leading Israeli medical cannabis industry and a successful track record bringing their research and innovations to market on an industrial scale," said Neil Closner, CEO of MedReleaf. "Our ability to iterate quickly and drive ongoing process improvements are a source of competitive ...
28 Aug 2017.
MARKHAM, ON, August 28, 2017 — MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"),Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, has been invited to present at the 2017 Gateway Conference , which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco. MedReleaf’s CEO, Neil Closner, is scheduled to present on Wednesday, September 6 at 3:30 p.m. Pacific time, with one-on-one meetings held throughout the conference. The presentation will be webcast live and available for replay in the Investor Relations section of MedReleaf’s website at http://investors.medreleaf.com/ or on the Gateway Conference website at www.gateway-conference.com/presenters . To receive additional information, request an invitation or to schedule a one-on-one meeting, please email gateway@liolios.com. About the Gateway Conference The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling ...
14 Aug 2017.
  MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the first quarter fiscal 2018 ending June 30, 2017 . All amounts expressed are in Canadian dollars unless otherwise noted. "Over the past two quarters, we have maintained our revenue run rate through the addition of new patient volumes and by growing cannabis-oil extract sales, which have successfully mitigated the anticipated impact of the Veterans Affairs Policy ("VAC") change," said Neil Closner, CEO of MedReleaf. "With our product mix from extracts increasing, the recent completion of our first harvest at our Bradford facility and our first successful international transaction in Brazil, we are well positioned for sustainable growth over the long-term." First Quarter Fiscal 2018 Financial Summary Three Months June 30, CAD$ (in 000s, except grams sold) 2017 2016 Dried Cannabis 8,573 8,582 ...
8 Aug 2017.
Pioneering transaction also marks first ever cannabis oil import to Brazil MedReleaf Corp. (TSX: LEAF) (MedReleaf or the "Company"), North America's first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products, today announced a milestone achievement with the completion of its first international export.  The transaction is also noteworthy as the first ever import of medical cannabis oil to Brazil and serves as a demonstration of both the Company's commitment to international growth and to establishing its position as the leading source of cannabis-based pharmaceutical products globally. The export is being made to treat the symptoms of Sofia Langenbach , a child who carries the CDKL5 genetic syndrome – leading her to experience refractory epilepsy and severe seizures which for her, has only been alleviated by the use of medical cannabis. Her mother, Ms. Margarette Santos de Brito , currently president of APEPI ("Support for Research and Medical ...
26 Jul 2017.
MedReleaf Corp. (TSX: LEAF), North America's first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products, today announced that it will hold a conference call to discuss its first quarter fiscal 2018 results on Monday, August 14, 2017 at 8:00 a.m. (ET) . The call will be hosted by Neil Closner , Chief Executive Officer, and Igor Gimelshtein , Chief Financial Officer, followed by a question and answer period. MedReleaf will report its financial results in the morning prior to the call. First Quarter Fiscal 2018 Conference Call Details: Date: Monday, August 14, 2017 Time: 8:00 a.m. (ET) Dial in number: (647) 427-7450 or 1-888-231-8191 Live webcast: http://bit.ly/2eEMhiZ Webcast will be archived for 90 days Replay: 1-855-859-2056 Available until August 21, 2017 Replay passcode: 59994102 Forward Looking Statements This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based ...
17 Jul 2017.
First Licenced Producer to bring innovative vaporizing technology to Canada MedReleaf Corp. (TSX: LEAF), North America's first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products, today announced a multi-year licensing and distribution agreement with Massachusetts-based CannaKorp Inc. ("CannaKorp"), makers of the world's first single-use, pod-based cannabis vaporizing system, the CannaCloud™. The CannaCloud is a pod-based cannabis vaporizing system that uses precisely measured, sealed and tested CannaCloud Pods ("cPods") containing dried, ground cannabis flower that will be produced and packaged by MedReleaf in Canada . The CannaCloud gives cannabis users the predictability and assurance to know what they are inhaling every time, without the hassle of grinding, measuring, and packing traditional vaporization consumption devices. "We are proud to partner with technology leaders like CannaKorp to be the first licensed producer in Canada to offer ...
28 Jun 2017.
MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the fourth quarter and fiscal year ended March 31, 2017 . All amounts expressed are in Canadian dollars unless otherwise noted. "We doubled revenue in fiscal 2017 and we did it profitably – growing Adjusted EBITDA more than threefold," said Neil Closner, CEO of MedReleaf. "With the successful completion of our IPO in June we have $74 million in financing to help fund our strategic growth initiatives including: expanding our capacity more than five times to support up to 35,000 kilograms of production; scaling our domestic business; developing our recreational brand portfolio; and international expansion, which we believe positions MedReleaf well for future growth and profitability." Fourth Quarter and Fiscal Year 2017 Financial Summary Three Months Twelve Months March 31, March 31, CAD$ (in 000s, ...
22 Jun 2017.
MedReleaf Corp. (TSX: LEAF), ("MedReleaf"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, announced today that Donald Courtney has been appointed Chief Operating Officer (COO). As a senior executive, Mr. Courtney brings to MedReleaf over twenty years of global operations and supply chain experience with large multi-national organizations in the wine, food, consumer packaged goods (CPG) and technology sectors. "Wine, technology, food and CPG are all very relevant to the future of the global cannabis industry and we are very pleased to welcome Don to our leadership team given his impressive track record in these industries," said Neil Closner, CEO of MedReleaf.  "Don brings the operational expertise necessary to support our continued growth while maintaining our industry-leading standards of product quality and production excellence." Mr. Courtney brings to MedReleaf a wealth of relevant experience including senior operational roles at Vincor International , ...
19 Jun 2017.
MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 certified cannabis producer, announced today that it has become the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices ("ICH-GMP") for Active Pharmaceutical Ingredients. MedReleaf's wide-ranging ICH-GMP compliance certification covers the Research and Development, Production, Distribution, Processing, Selling, and Destruction of medical cannabis for its Markham facility. Although there are a number of different GMP certifying bodies, the ICH-GMP is the globally accepted standard for the pharmaceutical industry recognized by regulatory authorities around the world including Canada , the United States , EU, Japan , Singapore and Australia . MedReleaf's ICH-GMP certification will support the Company's international growth and commitment to maintaining its position as the Medical Grade Standard in a number of ways, ...
16 Jun 2017.
MedReleaf Corp. (TSX: LEAF), Canada's first and only ISO 9001 certified cannabis producer, today announced that it will hold a conference call to discuss its fourth quarter and fiscal year 2017 results on Wednesday, June 28, 2017 at 8:00 a.m. (ET) . The call will be hosted by Neil Closner , Chief Executive Officer, and Igor Gimelshtein , Chief Financial Officer, followed by a question and answer period. MedReleaf will report its financial results in the morning prior to the call. Fourth Quarter and Fiscal Year 2017 Conference Call Details: Date: Wednesday, June 28, 2017 Time: 8:00 a.m. (ET) Dial in number: (647) 427-7450 or 1-888-231-8191 Live webcast: http://bit.ly/2rl9jgz Webcast will be archived for 90 days Replay: 1-855-859-2056 Available until July 5, 2017 Replay passcode: 41045544 About MedReleaf Corp. MedReleaf sets The Medical Grade Standard ™ for cannabis in Canada and around the world.  The first and only ISO 9001 certified cannabis producer in North America , MedReleaf is a ...
7 Jun 2017.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. MedReleaf Corp. ("MedReleaf") (TSX:LEAF) today announced the successful closing of its initial public offering and secondary offering of an aggregate of 10,600,000 common shares of MedReleaf at a price of $9.50 per common share (the "Offering Price") for aggregate gross proceeds of $100,700,000 , with MedReleaf and certain shareholders (the "Selling Shareholders") receiving gross proceeds of $80,700,049 and $19,999,951 , respectively. The common shares will commence trading today on the Toronto Stock Exchange under the symbol "LEAF". Pursuant to the Offering, MedReleaf issued 8,494,742 Offered Shares from treasury (the "Treasury Offering"). In addition, 2,105,258 Offered Shares were sold pursuant to a secondary offering (the "Secondary Offering") by the Selling Shareholders. MedReleaf will not receive any proceeds from the Secondary Offering. The Offering was managed by a syndicate of underwriters ...
30 May 2017.
MARKHAM, ONTARIO -(Marketwired - May 30, 2017 ) - NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MedReleaf Corp. ("MedReleaf" or the "Company") announced today that it has obtained a receipt for its final prospectus filed with the securities regulatory authorities in each of the provinces and territories of Canada in connection with the initial public offering and secondary offering (together, the "Offering") of an aggregate of 10,600,000 common shares (the "Offered Shares") of MedReleaf at a price of $9.50 per Offered Share (the "Offering Price") for aggregate gross proceeds of $100,700,000 , with MedReleaf and certain shareholders (the "Selling Shareholders") receiving gross proceeds of $80,700,049 and $19,999,951 , respectively. A copy of the final prospectus in respect of the Offering is available on SEDAR at www.sedar.com . Pursuant to the Offering, 8,494,742 Offered Shares will be issued by MedReleaf from treasury (the "Treasury Offering") ...
19 Apr 2017.
MedReleaf Corp. Announces Filing of Preliminary Prospectus for Initial Public Offering of Common Shares NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. MedReleaf Corp. (MedReleaf or the Company) announced today that it has filed a preliminary prospectus with the securities regulatory authorities in each of the provinces and territories of Canada, in connection with a proposed initial public offering (the Offering) of common shares (the Common Shares). The Offering is expected to include a treasury offering of Common Shares by the Company and a secondary offering of Common Shares by certain shareholders. The number of Common Shares to be sold and the price per common share have not yet been determined. A copy of the preliminary prospectus is available on SEDAR (www.sedar.com). The Offering will be made through a syndicate of underwriters co-led by GMP Securities L.P., who will also act as sole bookrunner. The preliminary prospectus has not yet ...
9 Mar 2017.
There have been recent reports and media coverage regarding the use of certain unapproved pesticides by some Licensed Producers of cannabis in Canada . MedReleaf is not amongst the companies alleged to have used unapproved agents, nor has it ever used these agents. As the first and only Licensed Producer with ISO 9001 certification, a global standard for quality management, Canadian patients should remain confident that MedReleaf will continue to lead with practices that exceed the regulatory standard for safety and quality in the Canadian cannabis industry. As such, the Company is supportive of Cannabis Canada Association's new proposed guideline and standards for Licensed Producers including confirmation of the Company's product testing protocols including bacteria, microbial, aflatoxins, heavy metals and pesticides. To further demonstrate leadership on this issue, MedReleaf will soon begin to provide our patients with access to a simplified Certificate of Analysis (CoA) ...
16 Feb 2017.
MedReleaf, Canada's premium licensed producer (LP) of medical cannabis, today announced it is providing same-day delivery to patients in the Greater Toronto Area (GTA). The same-day delivery service covers Mississauga , Vaughan , Richmond Hill , Brampton , Markham and Toronto. MedReleaf hopes the same-day service will encourage medical cannabis patients seeking quick access to medication to abandon unregulated dispensaries in favour of the safe, secure and regulated system. This announcement follows closely on another pioneering first for MedReleaf, becoming the first and only LP to receive Health Canada approval to sell cannabis capsules, a format that is favoured by physicians and patients alike as it allows for more consistent dosing. "Everything we do is driven by an unwavering commitment to our patients, the desire to lead Canada's medical cannabis industry and to strengthen our position as the country's premium licensed producer," noted Neil Closner , CEO of MedReleaf. "Being ...
14 Feb 2017.
  Ehave, Inc. (OTCQB:EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, and MedReleaf Corp. , Canada's premium medical cannabis licensed producer, today announced that the companies have entered into a partnership to develop a branded MedReleaf app utilizing the Ehave Connect mental health informatics platform to advance the study and therapeutic use of medical cannabis.  Ehave Connect enables developers, and ultimately prescribers, of medical cannabis to design and monitor treatment plans, track patient compliance, and verify treatment outcomes in a reliable and objective manner. Together, Ehave and MedReleaf seek to validate and optimize the use of MedReleaf's medical cannabis products as therapeutic treatments for various mental health conditions. Initially, the companies will use Ehave Connect to manage treatment plans and track patient outcomes as part of a clinical trial to evaluate medical ...